Polipyd’s Initial Public Offering


Yigal Arnon represented Barclays in the offering

PolyPid raised a $60 million in an initial public offering on Nasdaq.

PolyPid Ltd. operates as a pharmaceutical company, and discovers, develops, and commercializes antibiotic drugs for the prevention of surgical infections.

Barclays acted as underwriter in the IPO.

The Yigal Arnon team was led by Advs. Barry Levenfeld (Picture), Adrian Daniels, Noah Zivan, Vered Glaubach and intern Nitzan Bigman, and also included Shira Lahat, Daniel Green, Miriam Friedmann, Sophy Litvin, Dr. Eran Lempert, Assaf Mesica and Shai Margalit.

Involved fees earner: Nitzan Bigman – Yigal Arnon & Co; Adrian Daniels – Yigal Arnon & Co; Miriam Friedmann – Yigal Arnon & Co; Vered Glaubach – Yigal Arnon & Co; Daniel Green – Yigal Arnon & Co; Shira Lahat – Yigal Arnon & Co; Eran Lempert – Yigal Arnon & Co; Barry Levenfeld – Yigal Arnon & Co; Sophy Litvin – Yigal Arnon & Co; Shai Margalit – Yigal Arnon & Co; Assaf Mesica – Yigal Arnon & Co; Noah Zivan – Yigal Arnon & Co;

Law Firms: Yigal Arnon & Co;

Clients: Barclays Bank;

Author: Michael Patrini.